Clinical features of 171 SMZL patients with available survival data
| Feature . | n (%) . |
|---|---|
| Median age, y (range) | 67 (32-88) |
| Sex, male/female | 81/90 |
| ECOG ≥ 2 | 5 (7.1) |
| Splenomegaly | 112/138 (81.2) |
| Bone marrow involvement | 76/81 (93.8) |
| Lymphocytosis ≥ 5 × 109/L | 62/137 (45.3) |
| Villous lymphocytes | 34/52 (65.4) |
| LDH ≥ 450 mg/L | 28/91 (30.8) |
| β2-Microglobulin ≥ 3 mg/L | 48/81 (59.3) |
| Albumin ≤ 35 g/L | 17/74 (23) |
| Hb < 12 g/dL | 75/143 (52.4) |
| Platelet count ≤ 100 × 109/L | 31/143 (21.7) |
| M component | 16/41 (39) |
| HCV infection | 4/48 (8.3) |
| Autoimmune phenomena | 5/36 (13.8) |
| CD5 expression* | 26/115 (22.6) |
| IG gene rearrangements | |
| Unmutated† | 41/100 (41) |
| Mutated† | 59/100 (59) |
| IGHV1–2 | 32/100 (32) |
| Follow-up data | |
| Deaths | 69/171 (40.3) |
| Median overall survival, y (range) | 10.6 (0.4-18.8) |
| Median follow-up, y (range) | 5 (2 mo-25.3) |
| IIL score | |
| Low risk | 23/65 (35.4) |
| Intermediate risk | 20/65 (30.8) |
| High risk | 22/65 (33.8) |
| Treatment | |
| No therapy | 28/159 (17.6) |
| Splenectomy | 85/159 (53.5) |
| Chemotherapy | 23/159 (14.5) |
| Splenectomy + chemotherapy | 23/159 (14.5) |
| CR after therapy | 22/134 (16.4) |
| PR after therapy | 35/134 (26.1) |
| Stable disease | 11/134 (8.2) |
| Progression after initial therapy | 60/134 (44.8) |
| Nonresponse | 6/134 (4.5) |
| Feature . | n (%) . |
|---|---|
| Median age, y (range) | 67 (32-88) |
| Sex, male/female | 81/90 |
| ECOG ≥ 2 | 5 (7.1) |
| Splenomegaly | 112/138 (81.2) |
| Bone marrow involvement | 76/81 (93.8) |
| Lymphocytosis ≥ 5 × 109/L | 62/137 (45.3) |
| Villous lymphocytes | 34/52 (65.4) |
| LDH ≥ 450 mg/L | 28/91 (30.8) |
| β2-Microglobulin ≥ 3 mg/L | 48/81 (59.3) |
| Albumin ≤ 35 g/L | 17/74 (23) |
| Hb < 12 g/dL | 75/143 (52.4) |
| Platelet count ≤ 100 × 109/L | 31/143 (21.7) |
| M component | 16/41 (39) |
| HCV infection | 4/48 (8.3) |
| Autoimmune phenomena | 5/36 (13.8) |
| CD5 expression* | 26/115 (22.6) |
| IG gene rearrangements | |
| Unmutated† | 41/100 (41) |
| Mutated† | 59/100 (59) |
| IGHV1–2 | 32/100 (32) |
| Follow-up data | |
| Deaths | 69/171 (40.3) |
| Median overall survival, y (range) | 10.6 (0.4-18.8) |
| Median follow-up, y (range) | 5 (2 mo-25.3) |
| IIL score | |
| Low risk | 23/65 (35.4) |
| Intermediate risk | 20/65 (30.8) |
| High risk | 22/65 (33.8) |
| Treatment | |
| No therapy | 28/159 (17.6) |
| Splenectomy | 85/159 (53.5) |
| Chemotherapy | 23/159 (14.5) |
| Splenectomy + chemotherapy | 23/159 (14.5) |
| CR after therapy | 22/134 (16.4) |
| PR after therapy | 35/134 (26.1) |
| Stable disease | 11/134 (8.2) |
| Progression after initial therapy | 60/134 (44.8) |
| Nonresponse | 6/134 (4.5) |